论文部分内容阅读
左旋多巴及其脱羧酶抑制剂联用作为一种疗法以改善帕金森氏病的症状,为近十余年来抗帕金森氏病药物治疗的两大重大进展,也是神经介质在理论研究方面所取得的丰硕成果.但通过十多年的临床应用,逐渐注意到:不仅10～15%患者的左旋多巴血浆浓度虽达治疗水平仍无疗效,且开始对左旋多巴有疗效的患者中,不论患者属轻、中、重症,其疗效只能保持2～3年,以后逐渐下降,且出现不少限制左旋多巴使用的付作用.为了改善这种困境,一些研究工作者开辟了一条新的抗帕金森氏病的治疗途径,
L-DOPA and its decarboxylase inhibitors as a therapy to improve the symptoms of Parkinson’s disease for the past decade more than two major anti-Parkinson’s disease drug treatment, but also the nerve mediator in theoretical research But after more than 10 years of clinical application, it is gradually noticed that not only are the plasma concentrations of levodopa in 10 to 15% of the patients still refractory to the therapeutic level, but also the patients who have begun to respond to levodopa , Regardless of the patient is mild, moderate and severe, its efficacy can only be maintained for 2 to 3 years, then gradually declined, and there are many restrictions on the use of levodopa role.In order to improve this predicament, some researchers opened up a New anti-Parkinson’s disease treatment,